ArticleTransplantation direct2026
Eye Health Among Islet Cell Transplant Recipients With Long-duration Type 1 Diabetes.
Article in Transplantation direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is the commonest cause of blindness among people with type 1 diabetes (T1D) and can progress over time. In Australia, islet cell transplantation (ICT) is available for adults with T1D experiencing recurrent severe hypoglycemia. Rapid improvement in glycemia, which can occur post-ICT, may lead to "early worsening" of DR and warrants investigation. This study explored eye health outcomes among ICT recipients. Methods: This retrospective study examined all ICT recipients at a single tertiary institution in Victoria, Australia, 2007-2022 inclusive. Recipients of successful ICT, with available eye health information pre- and posttransplantation, were included. Eye health outcomes were assessed relative to ICT for changes in DR and other major retinal pathologies. Results: Sixteen recipients (30 eyes) with T1D duration median 31 y (interquartile range, 26-44) were followed up for 5 y (interquartile range, 4-9). At 12 mo post-ICT, hemoglobin A Conclusions: These findings highlight the potential positive impact of ICT to stabilize eye health among a small group of ICT recipients with long-duration type 1 diabetes. An extended systematic evaluation of eye health pre- and post-ICT is required to monitor both short-term and long-term eye health among transplant recipients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.